Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06099080 · ClinicalTrials.gov registry record · Phase 2
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)
A Phase 2 study of Dermatosis Papulosa Nigra, sponsored by DermBiont.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06099080 is a Phase 2 study of Dermatosis Papulosa Nigra that is active but no longer recruiting, run by DermBiont. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06099080, a Phase 2 study of Dermatosis Papulosa Nigra, is active but no longer recruiting, sponsored by DermBiont.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
An open-label trial to explore the safety and efficacy of SM-020 gel 1.0% in subjects with Dermatosis Papulosa Nigra (DPN). Approximately 10 subjects will be enrolled with DPNs to apply SM-020 gel 1.0%. Each subject must have a minimum of 5 eligible DPNTLs with a diameter ≥2mm but ≤5mm. A maximum of 10 DPNs per subject will be targeted for treatment. Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study. A total of 5-10 eligible Dermatosis Papulosa Nigra Target Lesions (DPNTLs) will be treated per subject.
Conditions Studied
Interventions
- DRUG SM-020 gel 1.0%
Study Locations (1)
California
- Vitiligo & Pigmentation Institute of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2024-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06099080
The ClinicalTrials.gov registry entry for NCT06099080 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DermBiont, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatosis Papulosa Nigra appearing as the primary indexed condition, and to 1 intervention - of which SM-020 gel 1.0% is the first listed.
NCT06099080 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06099080 about?
NCT06099080 is a clinical study titled "A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)". An open-label trial to explore the safety and efficacy of SM-020 gel 1.0% in subjects with Dermatosis Papulosa Nigra (DPN). Approximately 10 subjects will be enrolled with DPNs to apply SM-020 gel 1.0%. Each subject must have a minimum of 5 eligible DPNTLs with a diameter ≥2mm but ≤5mm. A maximum of...
What is the current status of trial NCT06099080?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-11-07. Estimated completion is 2024-07-25.
What conditions does trial NCT06099080 study?
This clinical trial studies the following conditions: Dermatosis Papulosa Nigra.
What interventions are being tested in trial NCT06099080?
The interventions under investigation include: SM-020 gel 1.0% (DRUG).
Who is sponsoring clinical trial NCT06099080?
This trial is sponsored by DermBiont, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06099080 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatosis Papulosa Nigra
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.